Daniel Menold - Aug 15, 2023 Form 4 Insider Report for CymaBay Therapeutics, Inc. (CBAY)

Role
Vice President, Finance
Signature
/s/ Paul Quinlan, as attorney-in-fact for Daniel Menold
Stock symbol
CBAY
Transactions as of
Aug 15, 2023
Transactions value $
$79,010
Form type
4
Date filed
8/16/2023, 04:59 PM
Previous filing
Aug 11, 2023
Next filing
Sep 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CBAY Common Stock Options Exercise $9.01K +8.5K $1.06* 8.5K Aug 15, 2023 Direct
transaction CBAY Common Stock Sale $0 0 $11.92 0 Aug 15, 2023 Direct F1, F2
transaction CBAY Common Stock Options Exercise $70K +7K $10.00 7K Aug 15, 2023 Direct
transaction CBAY Common Stock Sale $0 0 $12.13 0 Aug 15, 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CBAY Employee Stock Option (right to buy) Options Exercise $0 -8.5K -100% $0.00* 0 Aug 15, 2023 Common Stock 8.5K $1.06 Direct F4
transaction CBAY Employee Stock Option (right to buy) Options Exercise $0 -7K -100% $0.00* 0 Aug 15, 2023 Common Stock 7K $10.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on April 10, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.64 to $12.27, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.01 to $12.27, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The shares subject to the option became vested and exercisable according to the following schedule: 25% of the shares subject to the option vested on the first anniversary of the grant date, and the remaining shares vested in equal monthly installments over the next 36 months.